MedTrace Logo

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

NCT03821415 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2019-12-20

No results posted yet for this study

Summary

The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

RP101

17β-oestradiol-3-phosphate ophthalmic sterile solution

Sponsors & Collaborators

  • Cross Research S.A.

    collaborator INDUSTRY

  • Redwood Pharma AB

    lead INDUSTRY

Principal Investigators

  • Ulf Björklund, MSc Pharm · Redwood Pharma AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-18
Primary Completion
2019-11-18
Completion
2019-11-18

Countries

  • Austria
  • Germany
  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821415 on ClinicalTrials.gov